banner

Category Archives: Notes

Saudi Aramco Invests in Siluria’s Series D Financing

Siluria Technologies, is receiving a strategic investment from Saudi Aramco Energy Ventures (SAEV), the venture investment subsidiary of Saudi Aramco, as part of its Series D financing. The total raise for this initial close of Siluria’s Series D financing was $30 million, and included additional investments by all of the major existing investors in Siluria. … Continue reading Saudi Aramco Invests in Siluria’s Series D Financing

NovaBay Misses Endpoints in Phase 2 Trial in Adenoviral Conjunctivitis

NovaBay Pharma  (NYSE: NBY) today announced that its NVC-422 ophthalmic formulation did not meet the primary or secondary endpoints in a Phase 2 clinical study in patients with adenoviral conjunctivitis. NovaBay does not intend to initiate any new studies of NVC-422 for this indication. Going forward, the company is focusing its resources on the commercial launch … Continue reading NovaBay Misses Endpoints in Phase 2 Trial in Adenoviral Conjunctivitis

Rock Health Adds Eight Portfolio Companies and Three New Corporate Partners

On Tuesday, digital health-focused VC Rock Health announced the addition of eight companies to its portfolio.  With these additions, Rock Health has a diverse and active portfolio of 55 digital health companies across the country. The latest Rock Health companies include: Accountable: an online platform that guides companies step-by-step through the process of becoming HIPAA compliant. … Continue reading Rock Health Adds Eight Portfolio Companies and Three New Corporate Partners

Amgen’s Kyprolis Misses in Phase III FOCUS Trial in Refractory Multiple Myeloma

  Amgen, Inc.  (NASDAQ:AMGN) and its Onyx Pharmaceuticals subsidiary said Kyprolis carfilzomib as monotherapy missed the primary endpoint of improving overall survival (OS) vs. best supportive care (BSC) in the Phase III FOCUS trial to treat refractory multiple myeloma patients (HR=0.975, 95% CI: 0.76, 1.249). Amgen and Onyx said the incidence of renal adverse events was higher … Continue reading Amgen’s Kyprolis Misses in Phase III FOCUS Trial in Refractory Multiple Myeloma

Rigel’s R348 Did Not Meet Endpoints In Phase 2 Trial for Dry Eye

Rigel Pharmaceuticals, Inc. (RIGL) Wednesday said its ophthalmic JAK/SYK inhibitor, R348, did not meet the primary or secondary endpoints in a recently completed Phase 2 clinical study in patients with dry eye disease. <a target=”_top” href=”http://adclick.g.doubleclick.net/aclk%253Fsa%253DL%2526ai%253DB3gGwgI7rU_WANof8-QOJ6oKABtzL9JMFAAAAEAEgADgAWISOl-KlAWDJxv2GyKOgGYIBF2NhLXB1Yi0xNTg0MTA5OTcwODQ2NTY3sgEOd3d3Lm5hc2RhcS5jb226AQlnZnBfaW1hZ2XIAQnaAW5odHRwOi8vd3d3Lm5hc2RhcS5jb20vYXJ0aWNsZS9yaWdlbC1waGFybWEtcjM0OC1kaWQtbm90LW1lZXQtZW5kcG9pbnRzLWluLXBoYXNlLTItZHJ5LWV5ZS1zdHVkeS0yMDE0MDgxMy0wMDI0N8ACAuACAOoCIDMyNDQvbWt0c25ld3MubmFzZGFxLmNvbS9hcnRpY2xl-AL50R6QA6wCmAPgA6gDAdAEkE7gBAGgBiA%2526num%253D0%2526sig%253DAOD64_3e-c2vd6yyiPfNKD9BENGw36L5kA%2526client%253Dca-pub-1584109970846567%2526adurl%253Dhttp://screener.fidelity.com/ftgw/etf/goto/snapshot/snapshot.jhtml%3Fsymbols%3DONEQ”><img src=”” border=”0″ alt=”” ></a> The endpoints were measured by changes in corneal fluorescein staining, conjunctival staining, tear production and … Continue reading Rigel’s R348 Did Not Meet Endpoints In Phase 2 Trial for Dry Eye

23andMe Partners with Pfizer to Study Genetic Links to IBD

Pfizer and DNA testing firm 23andMe agreed to collaborate to uncover possible genetic mutations associated with inflammatory bowel disease. 23andMe will analyze saliva samples of 10,000 people with either Crohn’s disease or ulcerative colitis. “Our research objective is to understand the genetic associations found between IBD patients’ DNA and their disease, and apply this understanding … Continue reading 23andMe Partners with Pfizer to Study Genetic Links to IBD

Biotech Partners Appoints New Executive Director

Biotech Partners, an innovative career technical program that provides underserved Bay Area Youth with scientific professional development, has appointed Lynda Gayden as the new Executive Director. “Lynda brings a wealth of nonprofit experience and knowledge to Biotech Partners,” says Caroline Kane, Board President.   Most recently, Gayden served as Executive Director of Contra Costa Regional … Continue reading Biotech Partners Appoints New Executive Director